Related references
Note: Only part of the references are listed.Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study
Jun Inaishi et al.
BMC ENDOCRINE DISORDERS (2022)
The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study
Juraj Koska et al.
DIABETES CARE (2021)
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Radica Z. Alicic et al.
NATURE REVIEWS NEPHROLOGY (2021)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
Michael A. Nauck et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and safety of once-weekly exenatide after switching from twice-daily exenatide in patients with type 2 diabetes
Yuusuke Watanabe et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity
D. Weghuber et al.
PEDIATRIC OBESITY (2020)
Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: Apost hocanalysis of theEXSCELtrial
Annemarie B. van der Aart-van der Beek et al.
DIABETES OBESITY & METABOLISM (2020)
GLP-1 receptor agonists for Parkinson's disease
Caroline A. Mulvaney et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2020)
SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
Yoshifumi Saisho
DISEASES (2020)
The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
Sebastian M. Heimburger et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis
D. Giugliano et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2019)
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
Julio Rosenstock et al.
DIABETES CARE (2019)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study
Athena Philis-Tsimikas et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2019)
Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
Taichi Nagahisa et al.
DIABETES THERAPY (2019)
Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
M. Angelyn Bethel et al.
DIABETES (2018)
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study
Cristian Guja et al.
DIABETES OBESITY & METABOLISM (2018)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Recent updates on GLP-1 agonists: Current advancements & challenges
Dilip Sharma et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
Marcel H. A. Muskiet et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Andrew J. Ahmann et al.
DIABETES CARE (2018)
Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes
Sudhir Unni et al.
DIABETES OBESITY & METABOLISM (2018)
Exenatide: pharmacokinetics, clinical use, and future directions
Filip K. Knop et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda et al.
LANCET (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naive Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study
Lei Qin et al.
DIABETES THERAPY (2017)
Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naive Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study
Lei Qin et al.
DIABETES THERAPY (2017)
A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes
Stefano Genovese et al.
ADVANCES IN THERAPY (2017)
A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes
A. Brett Hauber et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
M. Nauck
DIABETES OBESITY & METABOLISM (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
Juan P. Frias et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
Qing Qiao et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2016)
Five-Year Efficacy and Safety Data of Exenatide Once Weekly: Long-term Results From the DURATION-1 Randomized Clinical Trial
Carol H. Wysham et al.
MAYO CLINIC PROCEEDINGS (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
Leigh MacConell et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2015)
Exenatide and the treatment of patients with Parkinson's disease
Iciar Aviles-Olmos et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
John B. Buse et al.
LANCET (2013)
Safety of exenatide once weekly for 52weeks in Japanese patients with type 2 diabetes mellitus
Yukiko Onishi et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
Linong Ji et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) A 26-week double-blind study
David Russell-Jones et al.
DIABETES CARE (2012)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
Encapsulation of Exenatide in Poly-(D,L-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
Mary Beth DeYoung et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
C. Wysham et al.
DIABETIC MEDICINE (2011)
DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
Thomas Blevins et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
DURATION-1 Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
John B. Buse et al.
DIABETES CARE (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
Dennis Kim et al.
DIABETES CARE (2007)
Share Paper
